Monocyclic Heteroaryl Compounds

1 . A compound of the Formula I, a tautomer, an individual isomer, a mixture of isomers or a pharmaceutically acceptable salt, solvate or hydrate thereof:

wherein:

Ring T represents a 5-membered monocyclic heteroaryl ring, comprising 1-3 heteroatoms selected from O, N and S;

Ring A represents a 5- or 6-membered aryl or heteroaryl ring;

Ring B represents a 5- or 6-membered aryl or heteroaryl ring;

L 1 is selected from NR 1 C(O) and C(O)NR 1 ;

each R a , R b and R t , is independently selected from the group consisting of halo, —CN, —NO 2 , —R 4 , —OR 2 , —NR 2 R 3 , —C(O)YR 2 , —OC(O)YR 2 , —NR 2 C(O)YR 2 , —SC(O)YR 2 , —R 2 C(═S)YR 2 , —OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 3 )YR 2 , —YP(═O)(YR 4 )(YR 4 ), —Si(R 4 ) 3 , —NR 2 SO 2 R 2 , —S(O) r R 2 , —SO 2 NR 2 R 3 and —NR 2 SO 2 NR 2 R 3 , wherein Y is independently a bond, —O—, —S— or —NR 3 —;

each R 1 , R 2 and R 3 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocycle and heteroaryl, and in addition, NR 2 R 3 moiety may be 5- or 6-membered saturated, partially saturated or unsaturated ring, which can be optionally substituted and which contains 0-2 additional heteroatoms selected from N, O and S(O) r ;

each R 4 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl;

each of the foregoing alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl moieties is optionally substituted;

m is 0, 1, 2, 3 or 4;

n is 0, 1, 2 or 3;

p is 0, 1, 2, 3, 4 or 5;

r is selected 0, 1 or 2.

2 . A compound according to claim 1 wherein Ring T is a monocyclic 5-membered ring selected from:

and is optionally substituted on carbon or heteroatom with 1-3 R t groups.

3 . A compound of claim 1 having the Formula:

wherein:

Ring C represents a 5- or 6-membered heterocyclic or heteroaryl ring, comprising carbon atoms and 1-3 heteroatoms selected from O, N and S(O) r and is optionally substituted on carbon or heteroatom(s) with 1-5 groups;

R e , at each occurrence, is independently selected from the group consisting of halo, ═O, ═S, —CN, —NO 2 , —R 4 , —OR 2 , —NR 2 R 3 , —C(O)YR 2 , —OC(O)YR 2 , —NR 2 C(O)YR 2 , —SC(O)YR 2 , —NR 2 C(═S)YR 2 , —OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 3 )YR 2 , —YP(═O)(YR 4 )(YR 4 ), —Si(R 4 ) 3 , —NR 2 SO 2 R 2 , —S(O) r R 2 , —SO 2 NR 2 R 3 and —NR 2 SO 2 NR 2 R 3 , wherein Y is independently a bond, —O—, —S— or —NR 3 —;

R 2 and R 3 are independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl;

alternatively, NR 2 R 3 moiety may be a 5- or 6-membered saturated, partially saturated or unsaturated ring, which can be optionally substituted and which contains 0-2 additional heteroatoms selected from N, O and S(O) r ;

each occurrence of R 4 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl;

each of the foregoing alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and heterocycle moieties is optionally substituted;

v is 0, 1, 2, 3, 4 or 5

t is 0, 1, 2, 3, or 4.

4 . A compound according to claim 3 , wherein Rings A and B are aryl.

5 . A compound of claim 3 wherein Ring C is a heteroaryl ring.

6 . A compound of claim 5 wherein Ring C is an imidazole ring.

7 . A compound of claim 3 selected from the formulae IIa, IIb and IIc:

8 . A compound of claim 7 wherein R t is independently selected from —CH 3 , or —C(O)NH 2 , v is 1, n is 0 or 1, m is 1, t is 1, R a is —CH 3 , R b is CF 3 and R c is —CH 3 .

9 . A compound of claim 1 having the Formula:

wherein:

Ring D represents a 5- or 6-membered heterocyclic or heteroaryl ring, comprising carbon atoms and 1-3 heteroatoms independently selected from N, O, S(O), and is optionally substituted with 1-5 R d groups;

L 2 is (CH 2 ) z , O(CH 2 ) x , NR 3 (CH 2 ) x , S(CH 2 ) x or (CH 2 ) x NR 3 C(O)(CH 2 ) x and the linkage unit can be used in either direction;

R d , at each occurrence, is selected from the group consisting of halo, ═O, ═S, —CN, —NO 2 , —R 4 , —OR 2 , —NR 2 R 3 , —C(O)YR 2 , —OC(O)YR 2 , —NR 2 C(O)YR 2 , —SC(O)YR 2 , —NR 2 C(═S)YR 2 , —OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 3 )YR 2 , —YP(═O)(YR 4 )(YR 4 ), —Si(R 4 ) 3 , —NR 2 SO 2 R 2 , —S(O) r R 2 , —SO 2 NR 2 R 3 and —NR 2 SO 2 NR 2 R 3 , wherein Y is independently a bond, —O—, —S— or —NR 3 —;

R 2 and R 3 are independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl;

alternatively, NR 2 R 3 moiety may be a 5- or 6-membered saturated, partially saturated or unsaturated ring, which can be optionally substituted and which contains 0-2 additional heteroatoms selected from N, O and S(O) r ;

each occurrence of R 4 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl;

each of the foregoing alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and heterocycle moieties is optionally substituted;

w is selected from 0, 1, 2, 3, 4 or 5;

x is 0, 1, 2 or 3;

z is 1, 2, 3 or 4; and

t is 0, 1, 2, 3, or 4.

10 . A compound according to claim 9 wherein Rings A and B are aryl.

11 . A compound of claim 9 wherein Ring D is a substituted or unsubstituted piperazine ring and L 2 is CH 2 .

12 . A compound of claim 9 wherein Ring D is a substituted or unsubstituted heteroaryl.

13 . A compound of claim 11 selected from Formulae IIIa, IIIb and IIIc:

14 . A compound of claim 13 wherein R t is independently selected from —CH 3 and —C(O)NH 2 , n is 0 or 1, m is 1, t is 1, R a is methyl, R b is CF 3 , one of R d is selected from methyl and CH 2 CH 2 OH.

15 . A method for treating cancer in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound of any of claims 1 - 14 or a pharmaceutically acceptable salt, solvate or hydrate thereof.

16 . A composition comprising a compound of any of claims 1 - 14 or a pharmaceutically acceptable salt, solvate or hydrate thereof and a pharmaceutically acceptable carrier, diluent or vehicle.